Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
NEW HAVEN, Conn., April 18, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 841,463 common shares at the public offering price, less underwriting discounts, and commissions. The gross proceeds from the offering are expected to be approximately $230 million before deducting underwriting discounts and commissions and offering expenses payable by Biohaven. The offering is expected to close on April 22, 2024, subject to satisfaction of customary closing conditions. Biohaven intends to use the net proceeds received from the offering for general corporate purposes.
J.P. Morgan, Morgan Stanley, TD Cowen, and Piper Sandler & Co. are acting as the joint lead book-running managers of the offering. Cantor is acting as a book-runner of the offering. Baird is also acting as a book-runner of the offering.
The offering is being made only by means of a prospectus supplement and the accompanying prospectus, copies of which, when available, may be obtained from the offices of the following: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com, Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (855) 495-9846 or by email at TD.ECM_Prospectus@tdsecurities.com, and Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at prospectus@psc.com.
The shares will be issued pursuant to an effective shelf registration statement on Form S-3. Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.
康涅狄格州紐黑文,2024年4月18日 /PRNewswire/ — 專注於在免疫學、神經科學和腫瘤學等關鍵治療領域發現、開發和商業化改變生活的療法的生物製藥公司Biohaven Ltd.(紐約證券交易所代碼:BHVN)今天宣佈,其承銷公開發行5,609,757股普通股的定價爲4美元每股 1.00 美元。此外,Biohaven已授予承銷商30天的期權,允許他們以公開發行價格(減去承銷折扣和佣金)額外購買最多841,463股普通股。在扣除承保折扣和佣金以及Biohaven應付的發行費用之前,此次發行的總收益預計約爲2.3億美元。此次發行預計將於2024年4月22日結束,但須滿足慣例成交條件。Biohaven打算將此次發行的淨收益用於一般公司用途。
摩根大通、摩根士丹利、道明考恩和派珀·桑德勒公司擔任此次發行的聯席牽頭賬面管理經理。坎託擔任此次發行的賬簿管理人。貝爾德還擔任此次發行的賬簿管理人。
此次發行僅通過招股說明書補充文件和隨附的招股說明書進行,其副本如果有,可從以下辦公室獲得:摩根大通證券有限責任公司,c/o Broadridge Financial Solutions,紐約州埃奇伍德長島大道 1155 號 11717,電話 (866) 803-9204,或發送電子郵件至 prospectus-eq_fi@jpmchase.com,摩根士丹利公司有限責任公司,收件人:招股說明書部,紐約州瓦里克街 180 號二樓 10014,紐約州紐約範德比爾特大道 1 號道明證券(美國)有限責任公司 10017,電話 (855) 495-9846 或發送電子郵件至 TD.ECM_Prospectus@tdsecurities.com,以及 Piper Sandler & Co.,800 Nicollet Mall,J12S03,明尼蘇達州明尼阿波利斯 55402,收件人:招股說明書部,致電 (800) 747-3924 或發送電子郵件至 prospectus@psc.com。
股票將根據S-3表格上的有效上架註冊聲明發行。可以通過美國證券交易委員會的網站訪問註冊聲明的副本,網址爲 www.sec.gov。本新聞稿不應構成出售要約或要求購買任何此類證券的要約,在根據該州或司法管轄區的適用證券法進行註冊或獲得資格認證之前,在任何州或司法管轄區出售此類證券是非法的,也不得在任何州或司法管轄區出售這些證券。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧